JOUNCE THERAPEUTICS INC (JNCE) Stock Price, Quote, News and Overview
NASDAQ:JNCE - Nasdaq - US4811161011 - Common Stock - Currency: USD
JNCE Quote, Performance and Key Statistics
1.88
-0.05 (-2.59%)
The current stock price of JNCE is 1.88 USD. In the past month the price increased by 0.53%. In the past year, price decreased by -65.76%.
JNCE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About JNCE
Company Profile
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 141 full-time employees. The company went IPO on 2017-01-26. The company is engaged in the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Its pipeline is focused on product candidates to address PD-(L)1-inhibitor resistant and PD-(L)1 inhibitor sensitive tumors. Its program, JTX-8064, is a tumor-associated macrophage candidate from its Translational Science platform. JTX-8064 is a monoclonal antibody that binds to Leukocyte Immunoglobulin Like Receptor B2, (LILRB2), which is a cell surface receptor expressed on macrophages and other myeloid cells. JTX-1484 is a monoclonal antibody designed to block human Leukocyte Immunoglobulin Like Receptor B4, (LILRB4) on various myeloid cells. Its product candidate, vopratelimab, is a monoclonal antibody that binds to and activates T cell CO-Stimulator (ICOS). The company also develops JTX-1484 and JTX-2134 product candidates.
Company Info
JOUNCE THERAPEUTICS INC
780 Memorial Drive
Cambridge MASSACHUSETTS 02139 US
CEO: Richard Murray
Employees: 141
Company Website: http://jouncetx.com/
Phone: 18572593840.0
JOUNCE THERAPEUTICS INC / JNCE FAQ
What is the stock price of JOUNCE THERAPEUTICS INC today?
The current stock price of JNCE is 1.88 USD. The price decreased by -2.59% in the last trading session.
What is the ticker symbol for JOUNCE THERAPEUTICS INC stock?
The exchange symbol of JOUNCE THERAPEUTICS INC is JNCE and it is listed on the Nasdaq exchange.
On which exchange is JNCE stock listed?
JNCE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for JOUNCE THERAPEUTICS INC stock?
13 analysts have analysed JNCE and the average price target is 1.65 USD. This implies a price decrease of -12.29% is expected in the next year compared to the current price of 1.88. Check the JOUNCE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is JOUNCE THERAPEUTICS INC worth?
JOUNCE THERAPEUTICS INC (JNCE) has a market capitalization of 98.95M USD. This makes JNCE a Micro Cap stock.
How many employees does JOUNCE THERAPEUTICS INC have?
JOUNCE THERAPEUTICS INC (JNCE) currently has 141 employees.
What are the support and resistance levels for JOUNCE THERAPEUTICS INC (JNCE) stock?
JOUNCE THERAPEUTICS INC (JNCE) has a support level at 1.87 and a resistance level at 1.91. Check the full technical report for a detailed analysis of JNCE support and resistance levels.
Is JOUNCE THERAPEUTICS INC (JNCE) expected to grow?
The Revenue of JOUNCE THERAPEUTICS INC (JNCE) is expected to decline by -100% in the next year. Check the estimates tab for more information on the JNCE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy JOUNCE THERAPEUTICS INC (JNCE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of JNCE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of JNCE, evaluating the profitability, health, valuation and growth aspects
- JOUNCE THERAPEUTICS INC (JNCE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- JOUNCE THERAPEUTICS INC (JNCE) Sales and EPS estimates to see what analysts future expectations are.
- JOUNCE THERAPEUTICS INC (JNCE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- JOUNCE THERAPEUTICS INC (JNCE) Insider and Institutional Ownership to learn about the owners and their transactions.
- JOUNCE THERAPEUTICS INC (JNCE) Stock Chart to make your own analysis
- JOUNCE THERAPEUTICS INC (JNCE) Latest news and press-releases to stay up to date.
Does JOUNCE THERAPEUTICS INC (JNCE) stock pay dividends?
JNCE does not pay a dividend.
When does JOUNCE THERAPEUTICS INC (JNCE) report earnings?
JOUNCE THERAPEUTICS INC (JNCE) will report earnings on 2023-08-02.
What is the Price/Earnings (PE) ratio of JOUNCE THERAPEUTICS INC (JNCE)?
JOUNCE THERAPEUTICS INC (JNCE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.99).
JNCE Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to JNCE. When comparing the yearly performance of all stocks, JNCE turns out to be only a medium performer in the overall market: it outperformed 50.11% of all stocks.
JNCE Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to JNCE. While JNCE seems to be doing ok healthwise, there are quite some concerns on its profitability.
JNCE Financial Highlights
Over the last trailing twelve months JNCE reported a non-GAAP Earnings per Share(EPS) of -0.99. The EPS increased by 46.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
JNCE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to JNCE. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of -37.55% and a revenue growth -100% for JNCE